Investigational drug · Phase 2
RV001V
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer Recurrent.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2021 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "RV001V"
First trial start
2019
Nov 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RV001V", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer Recurrent
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "RV001V" as an intervention, largest first.
- Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate CancerPivotal-lookingActive, not recruiting
RhoVac APSIndustry
NCT04114825 · 180 participants (planned) · Start Nov 19, 2019 · Primary completion Apr 2022
Drug: RV001V · For: Prostate Cancer Recurrent
Sites: Clearwater, Florida; Towson, Maryland; Omaha, Nebraska · 36 sites in all
AmgenAmgen (AMGN)
NCT01868997 · 88 participants · Start Jul 2013 · Primary completion Mar 2016
Drug: teprotumumab; normal saline · For: Thyroid Associated Ophthalmopathies; Thyroid-Associated Ophthalmopathy
Sites: Los Angeles, California; Aurora, Colorado; Atlanta, Georgia · 15 sites in all
RhoVac APSIndustry
NCT03199872 · 22 participants · Start Mar 30, 2017 · Primary completion Aug 1, 2018
Drug: RV001V · For: Prostate Cancer
Sites: Copenhagen, Denmark
AmgenAmgen (AMGN)
NCT02103283 · 5 participants · Start Oct 2014 · Primary completion Aug 2016
Drug: Teprotumumab · For: Diabetic Macular Edema
Sites: Beverly Hills, California; St. Petersburg, Florida; Omaha, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial.
Fresnillo Saló S, Schuhmacher J, Rahbech A, et al. · Vaccines (Basel) 2025
Also in development for Prostate Cancer Recurrent
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.